Also in CEL-SCI's pipeline are two other platforms, a Ligand Epitope Antigen Presentation System (L.E.A.P.S.)(TM) and Antigen-Directed Apoptosis (AdapT), with a second product candidate, CEL-1000. CEL-1000, derived from L.E.A.P.S.(TM), is poised for trials as a potential adjuvant to boost vaccine immunogenicity for viral encephalitis, herpes simplex, malaria, hepatitis B, and the avian flu.
About Crystal Research Associates, LLC
Crystal Research Associates, LLC is an independent research firm that provides institutional-quality, fee-based research to small and mid-cap companies. Crystal Research Associates' unique and novel product, the Executive Informational Overview(R) (EIO(R)), is free of investment ratings, target prices, and forward-looking financial models. The EIO(R) presents a crystal clear, detailed report on a company (public or private) in a manner that is easily understood by the Wall Street financial community. The EIO(R) details a company's product/technology/service offerings, market size(s), key intellectual property, leadership, growth strategy, competition, risks, audited financial statements, key events, and other such fundamental information. Crystal Research Associates has offices in New York City, Delray Beach, Montreal, and Toronto. Crystal Research Associates has been compensated by the Company in cash of thirty-five thousand U.S. dollars and two hundred thousand options/warrants to purchase CEL-SCI stock for its services in creating the base report, for updates, and for printing.
Forward-Looking Safe H
|SOURCE Crystal Research Associates, LLC|
Copyright©2007 PR Newswire.
All rights reserved